%0 PDF %T Plasma Cell Myeloma and Plasmacytoma-like Post-transplant Lymphoproliferative Disorders: A Survival Analysis in the Scientific Registry of Transplant Recipients. %A Rosenberg, Aaron. %D 2017-04-14T13:40:54.673Z %8 2017-04-14 %R http://localhost/files/9p290n51j %X Abstract: While recent studies and trials in post-transplant lymphoproliferative disorders (PTLD) have yielded important information regarding treatment and prognosis, relatively little is known about the rare subtypes plasmacytoma and plasma cell myeloma PTLD (PTLD-MM). Patients were identified in the Scientific Registry of Transplant Recipients between 1999-2011, overall survival (OS) estimated, and treatment trends evaluated. The effects of patient characteristics on OS were evaluated with Cox proportional hazards models. OS in PTLD-MM was compared to matched controls with multiple myeloma (MM) from the Surveillance, Epidemiology and End Results program. 214 patients with PTLD-MM were identified. Median OS in the whole cohort was 2.4 years. Median OS had not been reached in those diagnosed later in the study period, compared to < 2years in those diagnosed earlier (aHR 0.64, p=0.05). Advanced age, creatinine>2, Caucasian race and the use of OKT3 as an induction immunosuppressive agent were statistically significantly associated with diminished survival; extramedullary disease and poor performance status were nearly significant. When compared to matched controls, OS in PTLD-MM is worse than in MM (aHR 1.6, p<0.001), though improvement in OS over the last decade are more pronounced in PTLD-MM than in MM (p for interaction 0.02). Age at diagnosis, elevated creatinine, race and OKT3 were all associated with worse survival in patients with PTLD-MM. In contrast to prior studies, extramedullary disease was associated with increased risk of death. PTLD-MM is a rare disorder with poor prognosis, though dramatic improvements in OS over the last decade have outstripped those made in MM over the same time period.; Thesis (M.S.)--Tufts University, 2014.; Submitted to the Dept. of Clinical & Translational Science.; Advisors: Andreas Klein, and Robin Ruthazer.; Committee: Andreas Klein, Robin Ruthazer, David Kent, and Jessica Paulus.; Keyword: Oncology. %[ 2022-10-12 %9 Text %~ Tufts Digital Library %W Institution